Alpha Cognition (ACOG) Set to Post Earnings on Wednesday

Key Points

• Alpha Cognition is scheduled to report Q3 2026 results after the market closes on November 11; analysts expect a loss of $0.33 per share and revenue of $7.04 million.
• In its previous quarter, the company posted a loss of $0.40 per share, slightly worse than estimates, while revenue of $6.00 million exceeded the $4.38 million consensus.
• Analysts rate the stock a consensus Buy, with an average price target of $18.00; five analysts have Buy ratings.

Alpha Cognition (NASDAQ:ACOG - Get Free Report) is expected to be posting its Q3 2026 results after the market closes on Wednesday, November 11th. Analysts expect the company to post earnings of ($0.33) per share and revenue of $7.04 million for the quarter. Interested persons can check the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 4:30 PM ET.

Alpha Cognition (NASDAQ:ACOG - Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.01). The business had revenue of $6.00 million during the quarter, compared to the consensus estimate of $4.38 million. Alpha Cognition had a negative return on equity of 54.60% and a negative net margin of 153.61%. On average, analysts expect Alpha Cognition to post ($1.38) EPS for the current fiscal year and ($0.61) EPS for the next fiscal year.

Alpha Cognition Trading Up 4.0%

Alpha Cognition stock opened at $8.53 on Thursday. Alpha Cognition has a 52 week low of $4.50 and a 52 week high of $10.14. The business's 50-day simple moving average is $8.85 and its 200-day simple moving average is $7.19.

Insider Activity

In related news, Director Robert Wills acquired 10,000 shares of the business's stock in a transaction dated Friday, August 21st. The stock was acquired at an average price of $9.62 per share, with a total value of $96,200.00. Following the completion of the transaction, the director owned 32,241 shares of the company's stock, valued at approximately $310,158.42. This represents a 44.96% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 8.60% of the company's stock.

Wall Street Analysts Forecast Growth

ACOG has been the subject of several recent analyst reports. Raymond James Financial began coverage on Alpha Cognition in a research note on Friday, July 10th. They set an "outperform" rating and a $20.00 target price for the company. HC Wainwright lifted their price target on Alpha Cognition from $18.00 to $20.00 and gave the stock a "buy" rating in a research report on Monday, August 17th. Craig Hallum reaffirmed a "buy" rating and issued a $17.00 price target on shares of Alpha Cognition in a research report on Friday, August 14th. B. Riley Financial initiated coverage on Alpha Cognition in a report on Thursday, August 20th. They set a "buy" rating and a $21.00 price target for the company. Finally, Wall Street Zen raised Alpha Cognition from a "sell" rating to a "hold" rating in a research report on Saturday, August 15th. Five analysts have rated the stock with a Buy rating. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $18.00.

Alpha Cognition Company Profile

Alpha Cognition Inc is a biopharmaceutical company focused on developing and commercializing treatments for neurodegenerative diseases and cognitive disorders. The company's work is centered on therapies intended to address the medical needs of patients with Alzheimer's disease and other conditions affecting cognition.

Its lead commercial product is ZUNOVO (galantamine hydrobromide) extended-release capsules, an orally administered treatment approved by the U.S. Food and Drug Administration for mild-to-moderate dementia of the Alzheimer's type.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.